Nasal vaccine may aid fight against new viral variants

The emergence of COVID-19 variants such as delta and omicron have sent scientists scrambling to determine whether existing vaccinations and boosters are still effective against new strains of SARS-Cov-2.

A new response to the rapidly mutating virus might be found right at the door to our lungs, says Yale's Akiko Iwasaki, the Waldemar Von Zedtwitz Professor of Immunobiology. In a new study, she and her colleagues found that intranasal vaccination provides broad-based protection against heterologous respiratory viruses in mice, while so-called systemic immunization, which uses an injection to elicit body-wide protection, did not.

Their findings are published Dec. 10 in the journal Science Immunology.

"The best immune defense happens at the gate, guarding against viruses trying to enter," said Iwasaki, senior author of the study.

Mucous membranes contain their own immune defense system that combat air- or foodborne pathogens. When challenged, these barrier tissues produce B cells which in turn secrete immunoglobin A (IgA) antibodies. Unlike vaccines which elicit a system-wide immune response, IgA antibodies work locally on mucosal surfaces found in the nose, stomach, and lungs.

While the protective role of IgA-producing cells had been well established in combatting intestinal pathogens, Iwasaki's lab wondered if triggering IgA response might also produce a localized immune response against respiratory viruses.

Working with researchers at Icahn School of Medicine at Mount Sinai in New York, they tested a protein-based vaccine designed to jump start an IgA immune response, administering it to mice through injections, as is commonly done with systemic immunizations, and also intranasally. They then exposed mice to multiple strains of influenza viruses. They found that mice which had received vaccine intranasally were much better protected against the respiratory influenza than those that received injections. Nasal vaccines, but not the shot, also induced antibodies that protected the animals against a variety of flu strains, not just against the strain the vaccine was meant to protect against.

The Yale team is currently testing nasal vaccine strains against COVID strains in animal models.

While both vaccine injections and nasal vaccines increased levels of antibodies in the blood of mice, only the nasal vaccine enabled IgA secretion into the lungs, where respiratory viruses need to lodge to infect the host, Iwasaki said.

If the nasal vaccines prove to be safe and efficient in humans, Iwasaki envisions them being used in conjunction with current vaccines and boosters that work system wide in order to add immune system reinforcements at the source of infection.

Ji Eun Oh, Eric Song, Miyu Moriyama, Patrick Wong, Sophia Zhang, Ruoyi Jiang, Shirin Strohmeier, Steven H Kleinstein, Florian Krammer, Akiko Iwasaki.
Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA.
Science Immunology, 2021. doi: 10.1126/sciimmunol.abj5129

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...